- Home
- VANI vs ADVM Comparison
VANI vs ADVM Comparison
Compare VANI & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- ADVM
- Stock Information
- Founded
- VANI 1998
- ADVM 2006
- Country
- VANI United States
- ADVM United States
- Employees
- VANI N/A
- ADVM N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VANI Health Care
- ADVM Health Care
- Exchange
- VANI Nasdaq
- ADVM Nasdaq
- Market Cap
- VANI 75.8M
- ADVM 66.3M
- IPO Year
- VANI 2014
- ADVM 2014
- Fundamental
- Price
- VANI $1.47
- ADVM $2.95
- Analyst Decision
- VANI Strong Buy
- ADVM Strong Buy
- Analyst Count
- VANI 1
- ADVM 4
- Target Price
- VANI $4.00
- ADVM $19.75
- AVG Volume (30 Days)
- VANI 140.9K
- ADVM 72.6K
- Earning Date
- VANI 11-12-2025
- ADVM 11-03-2025
- Dividend Yield
- VANI N/A
- ADVM N/A
- EPS Growth
- VANI N/A
- ADVM N/A
- EPS
- VANI N/A
- ADVM N/A
- Revenue
- VANI N/A
- ADVM $1,000,000.00
- Revenue This Year
- VANI N/A
- ADVM $1,836.70
- Revenue Next Year
- VANI N/A
- ADVM N/A
- P/E Ratio
- VANI N/A
- ADVM N/A
- Revenue Growth
- VANI N/A
- ADVM N/A
- 52 Week Low
- VANI $0.91
- ADVM $1.78
- 52 Week High
- VANI $1.80
- ADVM $8.56
- Technical
- Relative Strength Index (RSI)
- VANI 63.68
- ADVM 47.83
- Support Level
- VANI $1.19
- ADVM $2.87
- Resistance Level
- VANI $1.55
- ADVM $3.23
- Average True Range (ATR)
- VANI 0.10
- ADVM 0.20
- MACD
- VANI 0.03
- ADVM -0.06
- Stochastic Oscillator
- VANI 80.49
- ADVM 11.11
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.